Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2020 | SAFIR02-IMMUNO: PDL1 copy number changes predicts checkpoint blockade inhibitor efficacy in mBC

Thomas Bachelot • 22 May 2020
ESMO Breast 2020
Breast Cancer Antibodies Durvalumab
SAFIR02-IMMUNO

Thomas Bachelot, MD, PhD, of Centre Léon Bérard, Lyon, France, discusses a subgroup analyses of the SAFIR02-IMMUNO study (NCT02299999) which aimed to determine the efficacy of genome analysis as a therapeutic decision tool for patients with metastatic breast cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Thomas Bachelot

2:10
Treating CNS metastases in HER2+ breast cancer
Thomas Bachelot • 21 Apr 2021
2:22
Sequencing therapies in HER2+ breast cancer
Thomas Bachelot • 21 Apr 2021

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals